Lack of association between statin use and angiographic and clinical outcomes after pipeline embolization for intracranial aneurysms

Waleed Brinjikji, H. Cloft, S. Cekirge, D. Fiorella, R. A. Hanel, P. Jabbour, P. Lylyk, C. McDougall, C. Moran, A. Siddiqui, I. Szikora, David F Kallmes

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE: Use of statin medications has been demonstrated to improve clinical and angiographic outcomes in patients receiving endovascular stent placement for coronary, peripheral, carotid, and intracranial stenoses. We studied the impact of statin use on long-term angiographic and clinical outcomes after flow-diverter treatment of intracranial aneurysms. MATERIALS AND METHODS: We performed a post hoc analysis from pooled patient-level datasets from 3 Pipeline Embolization Device studies: the International Retrospective Study of the Pipeline Embolization Device, the Pipeline for Uncoilable or Failed Aneurysms Study, and the Aneurysm Study of Pipeline in an Observational Registry. We analyzed data comparing 2 subgroups: 1) patients on statin medication, and 2) patients not on statin medication at the time of the procedure and follow-up. Angiographic and clinical outcomes were compared by using the χ2 test, Fisher exact test, or Wilcoxon rank sum test. RESULTS: We studied 1092 patients with 1221 aneurysms. At baseline, 226 patients were on statin medications and 866 patients were not on statin medications. The mean length of clinical and angiographic follow-up was 22.1±15.1 months and 28.3±23.7 months, respectively. There were no differences observed in angiographic outcomes at any time point between groups. Rates of complete occlusion were 82.8% (24/29) versus 86.4% (70/81) at 1-year (P = .759) and 93.3% (14/15) versus 95.7% (45/47) at 5-year (P = 1.000) follow-up for statin-versusnonstatin- use groups, respectively. There were no differences in any complication rates between groups, including major morbidity and neurologic mortality (7.5% versus 7.1%, P = .77). CONCLUSIONS: Our study found no association between statin use and angiographic or clinical outcomes among patients treated with the Pipeline Embolization Device.

Original languageEnglish (US)
Pages (from-to)753-758
Number of pages6
JournalAmerican Journal of Neuroradiology
Volume38
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Intracranial Aneurysm
Aneurysm
Nonparametric Statistics
Equipment and Supplies
Carotid Stenosis
Nervous System
Stents
Registries
Retrospective Studies
Morbidity
Mortality

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology

Cite this

Lack of association between statin use and angiographic and clinical outcomes after pipeline embolization for intracranial aneurysms. / Brinjikji, Waleed; Cloft, H.; Cekirge, S.; Fiorella, D.; Hanel, R. A.; Jabbour, P.; Lylyk, P.; McDougall, C.; Moran, C.; Siddiqui, A.; Szikora, I.; Kallmes, David F.

In: American Journal of Neuroradiology, Vol. 38, No. 4, 01.04.2017, p. 753-758.

Research output: Contribution to journalArticle

Brinjikji, W, Cloft, H, Cekirge, S, Fiorella, D, Hanel, RA, Jabbour, P, Lylyk, P, McDougall, C, Moran, C, Siddiqui, A, Szikora, I & Kallmes, DF 2017, 'Lack of association between statin use and angiographic and clinical outcomes after pipeline embolization for intracranial aneurysms', American Journal of Neuroradiology, vol. 38, no. 4, pp. 753-758. https://doi.org/10.3174/ajnr.A5078
Brinjikji, Waleed ; Cloft, H. ; Cekirge, S. ; Fiorella, D. ; Hanel, R. A. ; Jabbour, P. ; Lylyk, P. ; McDougall, C. ; Moran, C. ; Siddiqui, A. ; Szikora, I. ; Kallmes, David F. / Lack of association between statin use and angiographic and clinical outcomes after pipeline embolization for intracranial aneurysms. In: American Journal of Neuroradiology. 2017 ; Vol. 38, No. 4. pp. 753-758.
@article{5fc879b8ab0246008014d1943ac2f360,
title = "Lack of association between statin use and angiographic and clinical outcomes after pipeline embolization for intracranial aneurysms",
abstract = "BACKGROUND AND PURPOSE: Use of statin medications has been demonstrated to improve clinical and angiographic outcomes in patients receiving endovascular stent placement for coronary, peripheral, carotid, and intracranial stenoses. We studied the impact of statin use on long-term angiographic and clinical outcomes after flow-diverter treatment of intracranial aneurysms. MATERIALS AND METHODS: We performed a post hoc analysis from pooled patient-level datasets from 3 Pipeline Embolization Device studies: the International Retrospective Study of the Pipeline Embolization Device, the Pipeline for Uncoilable or Failed Aneurysms Study, and the Aneurysm Study of Pipeline in an Observational Registry. We analyzed data comparing 2 subgroups: 1) patients on statin medication, and 2) patients not on statin medication at the time of the procedure and follow-up. Angiographic and clinical outcomes were compared by using the χ2 test, Fisher exact test, or Wilcoxon rank sum test. RESULTS: We studied 1092 patients with 1221 aneurysms. At baseline, 226 patients were on statin medications and 866 patients were not on statin medications. The mean length of clinical and angiographic follow-up was 22.1±15.1 months and 28.3±23.7 months, respectively. There were no differences observed in angiographic outcomes at any time point between groups. Rates of complete occlusion were 82.8{\%} (24/29) versus 86.4{\%} (70/81) at 1-year (P = .759) and 93.3{\%} (14/15) versus 95.7{\%} (45/47) at 5-year (P = 1.000) follow-up for statin-versusnonstatin- use groups, respectively. There were no differences in any complication rates between groups, including major morbidity and neurologic mortality (7.5{\%} versus 7.1{\%}, P = .77). CONCLUSIONS: Our study found no association between statin use and angiographic or clinical outcomes among patients treated with the Pipeline Embolization Device.",
author = "Waleed Brinjikji and H. Cloft and S. Cekirge and D. Fiorella and Hanel, {R. A.} and P. Jabbour and P. Lylyk and C. McDougall and C. Moran and A. Siddiqui and I. Szikora and Kallmes, {David F}",
year = "2017",
month = "4",
day = "1",
doi = "10.3174/ajnr.A5078",
language = "English (US)",
volume = "38",
pages = "753--758",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "4",

}

TY - JOUR

T1 - Lack of association between statin use and angiographic and clinical outcomes after pipeline embolization for intracranial aneurysms

AU - Brinjikji, Waleed

AU - Cloft, H.

AU - Cekirge, S.

AU - Fiorella, D.

AU - Hanel, R. A.

AU - Jabbour, P.

AU - Lylyk, P.

AU - McDougall, C.

AU - Moran, C.

AU - Siddiqui, A.

AU - Szikora, I.

AU - Kallmes, David F

PY - 2017/4/1

Y1 - 2017/4/1

N2 - BACKGROUND AND PURPOSE: Use of statin medications has been demonstrated to improve clinical and angiographic outcomes in patients receiving endovascular stent placement for coronary, peripheral, carotid, and intracranial stenoses. We studied the impact of statin use on long-term angiographic and clinical outcomes after flow-diverter treatment of intracranial aneurysms. MATERIALS AND METHODS: We performed a post hoc analysis from pooled patient-level datasets from 3 Pipeline Embolization Device studies: the International Retrospective Study of the Pipeline Embolization Device, the Pipeline for Uncoilable or Failed Aneurysms Study, and the Aneurysm Study of Pipeline in an Observational Registry. We analyzed data comparing 2 subgroups: 1) patients on statin medication, and 2) patients not on statin medication at the time of the procedure and follow-up. Angiographic and clinical outcomes were compared by using the χ2 test, Fisher exact test, or Wilcoxon rank sum test. RESULTS: We studied 1092 patients with 1221 aneurysms. At baseline, 226 patients were on statin medications and 866 patients were not on statin medications. The mean length of clinical and angiographic follow-up was 22.1±15.1 months and 28.3±23.7 months, respectively. There were no differences observed in angiographic outcomes at any time point between groups. Rates of complete occlusion were 82.8% (24/29) versus 86.4% (70/81) at 1-year (P = .759) and 93.3% (14/15) versus 95.7% (45/47) at 5-year (P = 1.000) follow-up for statin-versusnonstatin- use groups, respectively. There were no differences in any complication rates between groups, including major morbidity and neurologic mortality (7.5% versus 7.1%, P = .77). CONCLUSIONS: Our study found no association between statin use and angiographic or clinical outcomes among patients treated with the Pipeline Embolization Device.

AB - BACKGROUND AND PURPOSE: Use of statin medications has been demonstrated to improve clinical and angiographic outcomes in patients receiving endovascular stent placement for coronary, peripheral, carotid, and intracranial stenoses. We studied the impact of statin use on long-term angiographic and clinical outcomes after flow-diverter treatment of intracranial aneurysms. MATERIALS AND METHODS: We performed a post hoc analysis from pooled patient-level datasets from 3 Pipeline Embolization Device studies: the International Retrospective Study of the Pipeline Embolization Device, the Pipeline for Uncoilable or Failed Aneurysms Study, and the Aneurysm Study of Pipeline in an Observational Registry. We analyzed data comparing 2 subgroups: 1) patients on statin medication, and 2) patients not on statin medication at the time of the procedure and follow-up. Angiographic and clinical outcomes were compared by using the χ2 test, Fisher exact test, or Wilcoxon rank sum test. RESULTS: We studied 1092 patients with 1221 aneurysms. At baseline, 226 patients were on statin medications and 866 patients were not on statin medications. The mean length of clinical and angiographic follow-up was 22.1±15.1 months and 28.3±23.7 months, respectively. There were no differences observed in angiographic outcomes at any time point between groups. Rates of complete occlusion were 82.8% (24/29) versus 86.4% (70/81) at 1-year (P = .759) and 93.3% (14/15) versus 95.7% (45/47) at 5-year (P = 1.000) follow-up for statin-versusnonstatin- use groups, respectively. There were no differences in any complication rates between groups, including major morbidity and neurologic mortality (7.5% versus 7.1%, P = .77). CONCLUSIONS: Our study found no association between statin use and angiographic or clinical outcomes among patients treated with the Pipeline Embolization Device.

UR - http://www.scopus.com/inward/record.url?scp=85017632692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017632692&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A5078

DO - 10.3174/ajnr.A5078

M3 - Article

VL - 38

SP - 753

EP - 758

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 4

ER -